Trial · NCT02183025
Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
NCT02183025, Phase 2, Completed, Boehringer Ingelheim
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea. Trials, record NCT02183025. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02183025
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety Study of Meloxicam Versus Mefenamic Acid in Patients With Dysmenorrhea
- NCT number
- NCT02183025
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 337 participants, actual
- Lead sponsor
- Boehringer Ingelheim
- Conditions
- Dysmenorrhea
- Interventions
- Meloxicam 7.5 mg, Meloxicam 15 mg, Mefenamic acid 500 mg, Placebo matching 7.5 mg meloxicam, Placebo matching 15 mg meloxicam, Placebo matching 500 mg mefenamic acid
- First posted
- 2014-07-08
- Last updated
- 2018-08-31
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluation of severity of lumbar and/or abdominal pain on a visual analogue scale (VAS) | Baseline and day 3-5 of each treatment cycle | |
| Secondary | Final global assessment of efficacy by patient on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Final global assessment of efficacy by investigator on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Final global assessment of tolerability by patient on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Final global assessment of tolerability by investigator on a 4-point scale | day 3-5 of the second treatment cycle | |
| Secondary | Number of Participants with Adverse Events (AE) | Up to 4 weeks after last treatment cycle | |
| Secondary | Incidence of significant laboratory events | Up to 4 weeks after last treatment cycle | |
| Secondary | Number of perforations, ulcerations and/or bleedings (PUB) of the upper gastro-intestinal tract | Up to 4 weeks after last treatment cycle | |
| Secondary | Number of gastro-intestinal adverse events (GI-AEs) | Up to 4 weeks after last treatment cycle | |
| Secondary | Duration of hospitalization stay due to GI-AEs | Up to 4 weeks after last treatment cycle |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02183025
GET https://conductscience.org/api/trials/v1/NCT02183025/registered